



June 2026 Quarterly Activities Report and Appendix 4C

- Promising cancer program results
- Noxopharm data for CSL presentation
- Prestigious journal recognises company's technology

Sydney, 22 July 2026: Australian clinical-stage drug development company **Noxopharm Limited (ASX:NOX)** provides its Quarterly Activities Report and Appendix 4C for the period ending 30 June 2026.

Cancer drug progress and CSL presentation

In the June quarter [Noxopharm announced new data](#) showing how the Sofra™ technology platform will be leveraged to fight cancer. The company is currently advancing a drug development program aimed at harnessing the power of Toll-like receptor 8 (TLR8) against cancer, and has now developed oligonucleotides capable of greatly amplifying the activity of TLR8 compared to current best in-class drugs in clinical development. This in turn stands to enhance the cancer-fighting activity of standard-of-care therapies like chemotherapy and radiotherapy. The immuno-oncology market is projected to grow from US\$35 billion in 2025 to US\$185 billion by 2035.

Additionally, Noxopharm announced its assets will be highlighted at an upcoming international conference. The data will be [presented by CSL](#), a global biopharma company, at the Options for the Control of Influenza XIII Conference in late August in Washington DC. The data itself relates to how Noxopharm's novel oligonucleotides from its Sofra technology platform could be used to improve the activity of self-amplifying mRNA vaccines.

In other collaboration news, Noxopharm revealed the first study results from a [European company testing Sofra assets](#). Belgium's InhaTarget Therapeutics is developing innovative treatments for lung-related diseases via a unique inhalation-based delivery system. Noxopharm signed a first Material Transfer Agreement with InhaTarget in October 2024, followed by a second one in May 2025 to enable the testing of a series of Sofra assets within the context of lung inflammation. Using Noxopharm's oligonucleotides, InhaTarget performed studies that showed successful encapsulation with an optimized LNP formulation and an over 75% reduction in lung inflammation in an animal model. The global market for inhaled therapies was valued at approximately US\$11.6 billion in 2024 and is projected to exceed US\$16 billion by 2034.

On the scientific front, the breakthrough discovery underlying Noxopharm's technology continues to gain attention, having been included in a new overview of the latest global research into the role of TLR7 in systemic lupus. A piece in the prestigious *Nature Reviews Rheumatology* journal represents high-level recognition of the collaborative work undertaken by Noxopharm, Hudson Institute of Medical Research, and an international team of researchers. This peer-reviewed validation reinforces how this discovery is changing our understanding of the immune system and supports further development of Noxopharm's pipeline. An article abstract is available here: <https://www.nature.com/articles/s41584-026-01388-0>

Noxopharm CEO Dr Olivier Laczka gave an interview to Proactive Investors in which he outlined his vision for the company, the breakthrough discovery underlying the Sofra platform, its potential as a cancer treatment, and the advantages the technology has in the marketplace. The interview lasts around 15 minutes and can be found here: <https://www.youtube.com/watch?v=2f9adjZDKlw>

Reflecting on the quarter, Dr Laczka said: “We are continuing to build very good momentum across the board. The progress we have made developing the Sofra platform and extending it into areas like cancer treatment shows how versatile the technology is – as further demonstrated by our ongoing external partnerships with companies around the world.

“Additionally, the start of SOF-SKN™ manufacturing, the new SOF-16 data, and the refinement of our dosing regimen stand us in good stead as we look towards and prepare for a clinical trial in patients.”

SOF-SKN™ and clinical trial update

During the quarter Noxopharm announced new data showing the potential of Sofra technology in samples from patients with autoimmune disease. In an [online manuscript](#), Hudson Institute of Medical Research’s Professor Michael Gantier and a team of international collaborators, including three Noxopharm employees plus collaborators from Tezcat Biosciences and InhaTarget Therapeutics, provided further insights and data demonstrating how the findings of the breakthrough [Nature Immunology paper](#) are being translated into the creation of new therapeutics. It represented the first time that SOF-16, the active ingredient in SOF SKN, had been tested on samples taken from patients with autoimmune diseases. The results showed that SOF-16 has potent anti-inflammatory activity in two *in vitro* studies, involving blood and joint fluid samples from patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis, respectively.

A layman’s explanation of the science underlying the *Nature Immunology* paper is on the Noxopharm [website](#), and a short interview with Professor Gantier can be found on the [Cytokine Society website](#). There is also a useful article and video on Hudson Institute’s website [here](#).

Noxopharm also [commenced SOF-SKN manufacturing](#), which involves a battery of physical, chemical and biological quality control tests and is taking place in a controlled environment, utilising a proven methodology that supports future efficiencies and low supply chain risks. Noxopharm will also use the manufactured product as part of preclinical investigations around dose range-finding experiments and therapeutic models, as well as further characterisation of SOF-SKN and its overall stability profile, which has been shown to be very good.

Additionally, the company published [promising new dosing regimen data](#) for SOF-SKN, which confirmed several important characteristics of the drug and represent a positive step in its refinement. This data will now form an important part of the submission package to regulatory authorities at the next stage of SOF-SKN’s clinical development.

In regulatory news, Noxopharm [engaged a globally recognised full-service clinical research organisation](#) (CRO) and scientific advisory company in the lead-up to a pre-Investigational New Drug (IND) meeting with the US Food & Drug Administration. The move will provide support to Noxopharm in preparing a data package suitable for a meeting with the FDA to discuss the planned clinical development pathway and requirements to support an IND application for SOF-SKN™. Pre-IND

meetings represent an important milestone in the drug development process and require significant planning.

SOF-SKN is initially being developed for the chronic inflammation caused by the autoimmune disease cutaneous lupus erythematosus (CLE), before potential development for other autoimmune-related skin diseases like psoriasis and dermatomyositis. The global CLE market is worth more than US\$3.3 billion and is expected to grow significantly over the coming years. The core Sofra™ technology could also be further utilised for rheumatoid arthritis and diabetes, plus other diseases linked to immune system dysregulation.

Autoimmune diseases are illnesses that make the body mistakenly attack itself, and lupus is just one of a wide range of these diseases that affect millions of people worldwide. Patient numbers have been steadily increasing over the past few decades, particularly in Westernised societies, with approximately 10% of the global population affected. This means that around 780 million people worldwide are living with various autoimmune diseases.

Financial update

- As of 30 June 2026, Noxopharm had A\$293k in cash.
- Net cash outflows from operating activities during the quarter amounted to A\$859k, compared to inflows of A\$848k in the quarter to 31 March 2026.
- The company made payments for research and development of A\$227k during the quarter, compared to A\$795k in the March 2026 quarter.
- The company continues to be vigilant with its cash resources and is exploring a range of options in relation to securing additional capital. It is looking at its strategic plan and exploring the likelihood of short-term catalysts which may impact the timing and range of options to secure follow-on funding.
- On 22 June 2026, the company entered into a short-term loan agreement with 4F Investments Pty Limited (a company associated with Chairman Fred Bart) for \$200,000. This loan is unsecured, attracts interest at 12% p.a., and is repayable on the company raising additional capital.
- In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C relate to director fees and salaries (including superannuation) for directors \$ 114,800.

-ENDS-

About the Sofra technology platform

Developed from a [breakthrough discovery](#) in innate immunology, the Sofra technology platform represents a revolutionary approach to drug design by translating a new understanding of innate biology into targeted therapeutics that enable precision control of disease-relevant signalling.

Sofra is based on the use of synthetic nucleic acids, known as oligonucleotides, to mimic natural regulators of the body's defence system.

This novel approach enables selective and modular tuning of immune sensors, reducing or stimulating their associated biological responses to mitigate a broad range of diseases and enhance RNA-based therapies and emerging therapeutic technologies.

[Sofra](#) is focused on inflammatory and autoimmune diseases such as rheumatoid arthritis, lupus and diabetes, as well as immuno-oncology for cancer treatment. The global autoimmune disease therapeutics market was worth US\$163.2 billion in 2024 and is expected to reach US\$219.6 billion by 2035, while the worldwide immuno-oncology market was US\$43 billion in 2023 and is projected to hit US\$284 billion by 2033.

Further information and animations: [SOF-SKN](#) / [SOF-VAC](#)

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

Shawn van Boheemen

T: +61 414 903 376

E: shawn.vanboheemen@noxopharm.com

Noxopharm CEO Dr Olivier Laczka has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

NOXOPHARM LIMITED

ABN

50 608 966 123

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(227)	(2,179)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(2)	(17)
(d) leased assets	-	-
(e) staff costs	(327)	(1,748)
(f) administration and corporate costs	(344)	(1,200)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	0	22
1.5 Interest and other costs of finance paid	42	(390)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	(859)	(2,705)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	(f) other non-current assets	-	-
	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	200	1,800
3.6	Repayment of borrowings	-	(350)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	200	1,450

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	952	1,545
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(859)	(2,705)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	200	1,450
4.5	Effect of movement in exchange rates on cash held	-	4
4.6	Cash and cash equivalents at end of period	293	293

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	293	952
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (business debit cards)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	293	952

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	115
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>The amount at 6.1 includes Director fees and salary (including superannuation) for directors and related parties and loan interest to a related party.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	4,050	4,050
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	5,000	-
7.4	Total financing facilities	9,050	4,050
7.5	Unused financing facilities available at quarter end		5,000
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. 1. Convertible notes, face value \$3.85M, interest rate 12% capitalised until maturity, expiry 2 January 2027; 2. Unsecured loan for \$200,000 provided by 4F investments Pty Ltd (a related party associated with the Chairman), 12% interest p.a. capitalised until repayment; 3. At The Market facility with Accuity Capital Investment Management Pty Ltd, facility limit \$5M, expiring 31 July 2031.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(859)
8.2	Cash and cash equivalents at quarter end (item 4.6)	293
8.3	Unused finance facilities available at quarter end (item 7.5)	5,000
8.4	Total available funding (item 8.2 + item 8.3)	5,293
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	6.17
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: Yes	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: In order to sustain the anticipated level of R&D activities, additional funding will be required. The precise timing, method and quantum of the additional funding to be secured remains subject to ongoing review and discussions between the Board as well as its advisers and potential funders. The timing of securing additional funds will also be subject to market conditions prevailing at the time. In addition, the Company continues to look for opportunities to apply for non-dilutive funding through government and other grants programs. The Company has a long and successful history of raising additional capital, be that in the form of equity or has recently been done, via the issue of Convertible Notes.	

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: The Company believes it has sufficient working capital to meet its obligations and continue with the implementation of its current business plans for the foreseeable future. Moreover, the Company is highly diligent in managing its ongoing cash reserves and will take the necessary steps to ensure that it remains a viable business.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: July 2026

Authorised by: ...By order of the Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.